J&J snags rights to a gene therapy portfolio from little MeiraGTx, a spinoff from Sam Waksal’s Kadmon

After getting a quick lesson on little MeiraGTx’s gene therapy efforts — including their home made on/off switch — J&J is going all in. And like other deals it’s made recently, J&J’s research organization under Mathai Mammen is demonstrating its enthusiasm for small biotechs that are short on history and long on promise.